ClinicalTrials.gg
CompletedNCT01255787Updated Dec 18, 2013Results posted

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

A Phase 2/3 interventional study of Vortioxetine and Placebo in Depressive Disorder, Major, sponsored by Takeda. Completed at 73 sites in 16 countries. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Takeda · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
14th of 54
600 · median 413
Started
2010
with 5 others
Phase 2/3
2 of 54
none open now
Registered
16th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 14th largest by enrollment, is one of 6 that started in 2010, is one of 2 in phase 2/3, and was the 16th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.

Read the detailed description

The drug that was tested in this study is called vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying doses of vortioxetine.

The study enrolled 600 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 5 mg
  • Vortioxetine 10 mg
  • Vortioxetine 20 mg
  • Placebo (dummy inactive pill) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-center trial was conducted in 14 countries in Europe and Asia. The overall time to participate in this study was up to 13 weeks. Participants made weekly visits to the clinic during the first 2 weeks of the 8-week treatment period and then every 2 weeks up to the end of the 8-week treatment period. Participants who completed the 8-week treatment period entered a 2-week discontinuation period to assess potential discontinuation symptoms 1 and 2 weeks after the end of the 8-week treatment period. A safety follow-up contact (visit or phone call) was made 4 weeks after completion of the 8-week double-blind treatment period (2 weeks after the end of the 2-week discontinuation period).

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • Major Depressive Disorder
  • Depression
  • Melancholia
  • Drug Therapy
04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Suffers from Major Depressive Disorder as the primary diagnosis according to , 4th Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.2x and 296.3x).
  2. The reported duration of the current major depressive episode is at least 3 months at the Screening Visit.
  3. Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Screening and Baseline Visits.
  4. Has a Clinical Global Impression Scale-Severity (CGI-S) score ≥4 at the Screening and Baseline Visits.

Exclusion criteria

Exclusion Criteria:

  1. Has one or more of the following conditions:

    • Any current psychiatric disorder other than Major Depressive Disorder as defined in the , 4th Edition, Text Revision (DSM-IV-TR; assessed by the Mini International Neuropsychiatric Interview: MINI). A participant who exhibits symptoms of anxiety is eligible unless fulfilling the diagnostic criteria for a current anxiety disorder per DSM-IV-TR.
    • Current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Current diagnosis or history of any substance-related disorder (except nicotine and caffeine-related disorders) as defined in the DSM-IV-TR. Participant with confirmed positive urine drug screens (except prescribed medications or a medication that does not constitute drug abuse) will be excluded.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder. (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, etc.)
    • Any DSM-IV-TR axis II disorder that might compromise the study.
  2. The current depressive symptoms of the participant are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
  3. Has received electroconvulsive, vagal nerve stimulation, or repetitive transcranial magnetic stimulation therapy within 6 months prior to the Screening Visit.
  4. Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  5. Is at significant risk of suicide or has a score ≥5 on Item 10 (suicidal thoughts) of the MADRS, or has attempted suicide within 6 months prior to the Screening Visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Placebo

    Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.

    Drug: Placebo

  • Experimental
    Vortioxetine 5 mg

    Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.

    Drug: Vortioxetine · Drug: Placebo

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.

    Drug: Vortioxetine · Drug: Placebo

  • Experimental
    Vortioxetine 20 mg

    Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.

    Drug: Vortioxetine · Drug: Placebo

Interventions

  • Vortioxetine tablets

    Also known as: Lu AA21004, Brintellix®

  • DrugPlacebo

    Vortioxetine placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment as a fixed factor and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Percentage of Participants With a MADRS Response at Week 8

    Response is defined as a participant with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Baseline and Week 8

  2. Percentage of Participants in MADRS Remission at Week 8

    Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Week 8

  3. Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8

    The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline Clinical Global Impression-Severity of Illness (CGI-S) score as a covariate.

    Time frame: Week 8

  4. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and family life or home responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

07

Results

Posted Dec 18, 2013

Participant flow

Participants took part in the study at 90 investigative sites in Japan, Europe and Asia/Oceania from 18 November 2010 to 25 April 2012.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
Started152144150154
Treated152144148150
Completed136127132132
Not completed16171822
Withdrew: Pretreatment event or adverse event (ae)6299
Withdrew: Major protocol deviation1104
Withdrew: Lost to follow-up1242
Withdrew: Withdrawal of consent3934
Withdrew: Pregnancy0001
Withdrew: Lack of efficacy2222
Withdrew: Noncompliance with study drug3100

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment as a fixed factor and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
scores on a scalePlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-13.99 ± 0.783-14.61 ± 0.805-15.68 ± 0.791-15.82 ± 0.786
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.9070 (Adjustment for multiplicity for the comparisons was based on the Dunnett-Hsu procedure.) · Ls mean difference: -0.61 · 95% CI -3.258 to 2.035Analysis of covariance (ANCOVA), with treatment as a fixed factors and baseline MADRS as a covariate.
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.3006 · Ls mean difference: -1.69 · 95% CI -4.310 to 0.938Analysis of covariance (ANCOVA), with treatment as a fixed factors and baseline MADRS as a covariate.
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.2399 · Ls mean difference: -1.82 · 95% CI -4.436 to 0.794Analysis of covariance (ANCOVA), with treatment as a fixed factors and baseline MADRS as a covariate.
SecondaryPercentage of Participants With a MADRS Response at Week 8

Response is defined as a participant with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a MADRS Response at Week 8
percentage of participantsPlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
Percentage of Participants With a MADRS Response at Week 839.349.354.451.0
SecondaryPercentage of Participants in MADRS Remission at Week 8

Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants in MADRS Remission at Week 8
percentage of participantsPlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
Percentage of Participants in MADRS Remission at Week 826.724.629.330.9
SecondaryMean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8

The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline Clinical Global Impression-Severity of Illness (CGI-S) score as a covariate.

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8
scores on a scalePlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 82.54 ± 0.0872.37 ± 0.0892.27 ± 0.0882.36 ± 0.087
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and family life or home responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
scores on a scalePlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8-6.20 ± 0.602-6.38 ± 0.647-7.97 ± 0.633-7.26 ± 0.622

Adverse events

Collected over A treatment-emergent adverse event is defined as any AE whose onset occurs or intensity increases after the first dose of double-blind study medication through 2 weeks after the last dose of double-blind study medication.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/151 (0.7%)97/151 (64.2%)
Vortioxetine 5 mg—2/144 (1.4%)96/144 (66.7%)
Vortioxetine 10 mg—2/148 (1.4%)93/148 (62.8%)
Vortioxetine 20 mg—3/150 (2%)106/150 (70.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
SyncopeNervous system disorders0/1511/1440/1480/150
Renal colicRenal and urinary disorders0/1511/1440/1480/150
GastroenteritisInfections and infestations0/1510/1441/1480/150
DepressionPsychiatric disorders0/1510/1441/1480/150
PyelonephritisInfections and infestations0/1510/1440/1481/150
Abortion missedPregnancy, puerperium and perinatal conditions0/1510/1440/1481/150
Suicide attemptPsychiatric disorders1/1510/1440/1481/150
Suicidal ideationPsychiatric disorders0/1510/1440/1481/150
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mg
NauseaGastrointestinal disorders11/15126/14427/14837/150
NasopharyngitisInfections and infestations18/15124/14418/14821/150
HeadacheNervous system disorders21/15116/14419/14823/150
DiarrhoeaGastrointestinal disorders14/1517/1446/1485/150
DizzinessNervous system disorders5/1517/1448/14810/150
Dry mouthGastrointestinal disorders3/1513/1446/1489/150
InsomniaPsychiatric disorders2/1514/1444/1489/150
ConstipationGastrointestinal disorders3/1516/1445/1488/150
SomnolenceNervous system disorders2/1517/1447/1486/150
FatigueGeneral disorders2/1516/1444/1485/150

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Mean43.6 ± 11.5744.2 ± 11.8945.7 ± 10.9044.0 ± 11.7944.4 ± 11.54
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Female91989393375
Male61465761225
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Caucasian (or White, including Hispanic)104101104105414
Asian48434649186
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Croatia01023
Finland555520
Germany50505049199
India333211
Japan33323133129
Latvia322310
Malaysia20024
Philippines424313
Poland2018202179
Romania546318
Russia1313121351
Serbia22329
South Korea667827
Ukraine667827
Height
Height(cm)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Mean167.1 ± 8.75167.2 ± 9.64167.5 ± 9.40167.5 ± 9.61167.3 ± 9.33
Weight
Weight(kg)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Mean69.70 ± 16.90170.57 ± 18.21473.37 ± 19.01470.21 ± 18.18970.95 ± 18.095
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Mean24.82 ± 5.12925.06 ± 5.43225.93 ± 5.46224.82 ± 5.20625.15 ± 5.313
Smoking Classification
Smoking Classification(participants)PlaceboVortioxetine 5 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Current smoker51505056207
Ex-smoker2219211173
Never smoked79757987320

7 further baseline measures are reported on the registry.

08

Study locations

73 sites
  • Split, Croatia
  • Zagreb, Croatia
  • Helsinki, Finland
  • Kuopio, Finland
  • Oulu, Finland
  • Tampere, Finland
  • Berlin, Germany
  • Bochum, Germany
  • Chemnitz, Germany
  • Hannover, Germany
  • Leipzig, Germany
  • Munchen, Germany
  • Nuernberg, Germany
  • Schwerin, Germany
  • Westerstede, Germany
  • Wiesbaden, Germany
  • Hong Kong, Hong Kong
  • Hyderabad, Andhra Pradesh, India
  • Ahmedabad, Gujarat, India
  • Lucknow, Uttar Pradesh, India
  • Varanasi, Uttar Pradesh, India
  • Kanpur, UttarPradesh, India
  • Tokoname-shi, Aichi, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kitakyushu-shi, Fukuoka, Japan
  • Omuta-shi, Fukuoka, Japan
  • Shirakawa-shi, Fukushima, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Tokyo, Japan
  • Sungnam-si, Gyeonggi-do, Korea, Republic of
  • Incheon, Korea, Korea, Republic of
  • Seoul, Korea, Korea, Republic of
  • Yangsan-si, Korea, Korea, Republic of
  • Liepaja, Latvia
  • Riga, Latvia
  • Sigulda, Latvia
  • Johor Bahru, Malaysia
  • Kuala Lumpur, Malaysia
  • Makati City, NCR, Philippines
  • Mandaluyong City, NCR, Philippines
  • Manila, NCR, Philippines
  • Quezon City, NCR, Philippines
  • Bialystok, Poland
  • Gorlice, Poland
  • Leszno, Poland
  • Torun, Poland
  • Zuromin, Poland
  • Iasi, Lasi, Romania
  • Targu Mures, Mures, Romania
  • Bucharest, Romania
  • Bucuresti, Romania
  • Ekaterinburg, Russia, Russian Federation
  • Nizhny Novgorod, Russia, Russian Federation
  • Rostov on Don, Russia, Russian Federation
  • Saint-Petersburg, Russia, Russian Federation
  • Smolensk, Russia, Russian Federation
  • St. Petersburg, Russia, Russian Federation
  • Stavropol, Russia, Russian Federation
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Senta, Serbia
  • Changhua, Taiwan
  • Kaohsiung City, Taiwan
  • Taipei City, Taiwan
  • Taipei, Taiwan
  • Taoyuan Hsien, Taiwan
  • Chernigiv region, Ukraine
  • Dnipropetrovsk, Ukraine
  • Kharkiv,, Ukraine
  • Kiev, Ukraine
  • Lugansk, Ukraine
09

References and documents

Publications

  • Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Psychiatry Clin Neurosci. 2018 Feb;72(2):64-72. doi: 10.1111/pcn.12565. Epub 2017 Oct 3. PubMed 28858412 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Mar 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2010
First posted
Dec 7, 2010
Start
Nov 2010
Primary completionActual
Mar 2012
CompletionActual
Apr 2012
Results first posted
Dec 18, 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01255787
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 7, 2010
Start date
Nov 2010
Primary completion
Mar 2012
Completion
Apr 2012
Results posted
Dec 18, 2013
Last update
Dec 18, 2013

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion